Last reviewed · How we verify
Mifepristone plus one dose Misoprostol
Mifepristone plus one dose Misoprostol is a Progesterone antagonist + prostaglandin analog Small molecule drug developed by Planned Parenthood League of Massachusetts. It is currently in Phase 3 development for Medical abortion (termination of intrauterine pregnancy up to 10 weeks gestation).
Mifepristone blocks progesterone receptors to stop pregnancy development, followed by misoprostol to induce uterine contractions and expel pregnancy tissue.
Mifepristone blocks progesterone receptors to stop pregnancy development, followed by misoprostol to induce uterine contractions and expel pregnancy tissue. Used for Medical abortion (termination of intrauterine pregnancy up to 10 weeks gestation).
At a glance
| Generic name | Mifepristone plus one dose Misoprostol |
|---|---|
| Sponsor | Planned Parenthood League of Massachusetts |
| Drug class | Progesterone antagonist + prostaglandin analog |
| Target | Progesterone receptor (PR) + prostaglandin E1 receptor (EP receptor) |
| Modality | Small molecule |
| Therapeutic area | Reproductive Health / Obstetrics |
| Phase | Phase 3 |
Mechanism of action
Mifepristone is a progesterone antagonist that prevents the hormone from maintaining the uterine lining and pregnancy. Misoprostol, a prostaglandin analog, is then administered to stimulate uterine contractions and facilitate expulsion of pregnancy tissue. Together, this combination achieves medical abortion through complementary mechanisms.
Approved indications
- Medical abortion (termination of intrauterine pregnancy up to 10 weeks gestation)
Common side effects
- Vaginal bleeding/heavy bleeding
- Abdominal pain/cramping
- Nausea
- Vomiting
- Diarrhea
- Dizziness
- Headache
- Fever/chills
Key clinical trials
- Mifepristone and Misoprostol for Undesired Pregnancy of Unknown Location (PHASE3)
- Assessing Outpatient 'Day Procedure' for Second-trimester Medical Abortion at Two Public Sector Hospitals in Nepal (PHASE4)
- Advance Provision of Medication Abortion (PHASE4)
- Outpatient Service for Mid-trimester Termination of Pregnancy (PHASE4)
- Medical Abortion With Mifepristone + Misoprostol (13 - 22 Weeks) (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Mifepristone plus one dose Misoprostol CI brief — competitive landscape report
- Mifepristone plus one dose Misoprostol updates RSS · CI watch RSS
- Planned Parenthood League of Massachusetts portfolio CI
Frequently asked questions about Mifepristone plus one dose Misoprostol
What is Mifepristone plus one dose Misoprostol?
How does Mifepristone plus one dose Misoprostol work?
What is Mifepristone plus one dose Misoprostol used for?
Who makes Mifepristone plus one dose Misoprostol?
What drug class is Mifepristone plus one dose Misoprostol in?
What development phase is Mifepristone plus one dose Misoprostol in?
What are the side effects of Mifepristone plus one dose Misoprostol?
What does Mifepristone plus one dose Misoprostol target?
Related
- Drug class: All Progesterone antagonist + prostaglandin analog drugs
- Target: All drugs targeting Progesterone receptor (PR) + prostaglandin E1 receptor (EP receptor)
- Manufacturer: Planned Parenthood League of Massachusetts — full pipeline
- Therapeutic area: All drugs in Reproductive Health / Obstetrics
- Indication: Drugs for Medical abortion (termination of intrauterine pregnancy up to 10 weeks gestation)
- Compare: Mifepristone plus one dose Misoprostol vs similar drugs
- Pricing: Mifepristone plus one dose Misoprostol cost, discount & access